Cytokinetics, Incorporated
Informe acción NasdaqGS:CYTK
Capitalización de mercado: US$6.8b
Salud financiera de hoja de balance de Cytokinetics
Salud financiera controles de criterios 2/6 Cytokinetics tiene un patrimonio de los accionistas total de $-13.9M y una deuda total de $656.0M, lo que sitúa su ratio deuda-patrimonio en -4715.8%. Sus activos y pasivos totales son $1.4B y $1.4B respectivamente.
Información clave
-4,715.8%
Ratio deuda-patrimonio
Ratio de cobertura de intereses n/a Efectivo US$1.01b Patrimonio -US$13.91m Total pasivo US$1.45b Activos totales US$1.44b
Actualizaciones recientes sobre salud financiera
Mostrar todas las actualizaciones
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 Nov 12
Now 20% overvalued after recent price rise Nov 11
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 07
Insider notifies of intention to sell stock Nov 01
Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Insider notifies of intention to sell stock Oct 17
Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions Sep 28
Consensus revenue estimates decrease by 23% Sep 05 Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Insider notifies of intention to sell stock Aug 22
Consensus revenue estimates fall by 54% Aug 16
CEO, President & Director notifies of intention to sell stock Aug 14
Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities Aug 13
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load? Aug 11
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 09
CEO, President & Director notifies of intention to sell stock Aug 01
Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes Jul 24
CEO, President & Director recently sold US$622k worth of stock Jul 02
Consensus revenue estimates increase by 10% Jun 25
CEO, President & Director recently sold US$1.2m worth of stock Jun 18
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants Jun 18
CEO, President & Director notifies of intention to sell stock Jun 09
VP & Chief Accounting Officer recently sold US$636k worth of stock Jun 06
New minor risk - Insider selling Jun 05 Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC May 30
Price target decreased by 7.5% to US$86.06 May 28
Consensus revenue estimates increase by 41% May 24
Cytokinetics Decides To Go It Alone May 24 Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.
Consensus revenue estimates decrease by 13% May 19
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors May 18
Insider notifies of intention to sell stock May 09
Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being May 09 Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment
Consensus revenue estimates decrease by 12% May 02
Independent Chairman notifies of intention to sell stock Apr 28 Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024 Apr 26
Insider exercised options and sold US$1.9m worth of stock Apr 10
Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024 Apr 09
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session Apr 05
Cytokinetics, Incorporated: Buyout Speculation Persists Apr 01
Cytokinetics: CEO Talks Down Buyout Prospects Mar 16
Insider notifies of intention to sell stock Mar 07
Consensus revenue estimates decrease by 49%, EPS upgraded Mar 06
Cytokinetics, Incorporated Provides Revenue Guidance for 2024 Feb 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 28
Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024 Feb 14
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024 Feb 05
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024 Feb 04
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024 Feb 03
CEO, President & Director notifies of intention to sell stock Feb 02
CEO, President & Director notifies of intention to sell stock Jan 22
Novartis Pursuit of Cytokinetics Reportedly Cools Jan 13
Novartis Pursuit of Cytokinetics Reportedly Cools Jan 12
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade) Jan 12
Novartis Reportedly in Advanced Talks to Buy Cytokinetics Jan 10 Novartis Reportedly in Advanced Talks to Buy Cytokinetics Jan 09
CEO, President & Director notifies of intention to sell stock Jan 04
Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Dec 28
New major risk - Revenue and earnings growth Dec 28
Price target increased by 20% to US$74.39 Dec 27
CEO, President & Director notifies of intention to sell stock Dec 20
Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND Dec 08
Now 23% undervalued after recent price drop Dec 05
CEO, President & Director exercised options and sold US$329k worth of stock Dec 04
Insufficient new directors Dec 01
CEO, President & Director notifies of intention to sell stock Nov 17
Now 22% undervalued Nov 10
New minor risk - Shareholder dilution Nov 05
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 03
CEO, President & Director exercised options and sold US$319k worth of stock Oct 31
Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023 Oct 24
Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day Oct 20
CEO, President & Director notifies of intention to sell stock Oct 18
CEO, President & Director notifies of intention to sell stock Oct 09
Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society Oct 08
An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued Oct 05
CEO, President & Director notifies of intention to sell stock Sep 15
Now 20% undervalued after recent price drop Sep 11
CEO, President & Director notifies of intention to sell stock Aug 28
CEO, President & Director exercised options and sold US$628k worth of stock Aug 14
Análisis de la situación financiera
Pasivos a corto plazo: CYTK tiene patrimonio neto negativo . Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo .
Pasivo a largo plazo: CYTK tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo .
Historial y análisis de deuda-patrimonio
Nivel de deuda: CYTK tiene patrimonio negativo , una situación más grave que un alto nivel de endeudamiento.
Reducción de la deuda: CYTK tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.
Análisis de cash runway En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CYTK tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CYTK dispone de suficiente cash runway para 1.9 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 34.9% cada año.
Descubre empresas con salud financiera Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
